Intravenous versus subcutaneous EPO: Is the cost benefit acceptable? Reply

被引：2

作者：

Besarab, A ^{[1
]}

Reyes, C

Hornberger, J

机构：

[1] Henry Ford Hosp, Div Nephrol & Hypertens, Detroit, MI 48202 USA

[2] Zynx Hlth Inc, Beverly Hills, CA USA

[3] Acumen LLC, Burlingame, CA USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2003年 / 41卷 / 05期

关键词：

D O I：

10.1016/S0272-6386(03)00289-0

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：1122 / 1123

页数：2

共 8 条

[1]

[Anonymous], 1999, Nephrol Dial Transplant, V14 Suppl 5, P1

[2]

[Anonymous], 2000, AM J KIDNEY DIS S, V37, pS182

[3]

Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients [J].

Besarab, A ;

Reyes, CM ;

Hornberger, J .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (03) :439-446

[4]

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. [J].

Casadevall, N ;

Nataf, J ;

Viron, B ;

Kolta, A ;

Kiladjian, J ;

Martin-Dupont, P ;

Michaud, P ;

Papo, T ;

Ugo, V ;

Teyssandier, I ;

Varet, B ;

Mayeux, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) :469-475

[5]

Casadevall N, 2002, NEW ENGL J MED, V346, P1585

[6]

CASADEVALL N, 2002, NEW ENGL J MED, V347, P458

[7]

Gershon SK, 2002, NEW ENGL J MED, V346, P1584

[8]

LEVIN A, 2002, COMMUNICATION 0815

← 1 →